SARASOTA, Fla., June 26, 2024 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological disorders, today announced the closing of its public offering of 1,100,000 shares of its common stock at an offering price of $1.00 per share. The offering was made pursuant to a shelf registration statement on Form S-3 (File No. 333-269225), including a base prospectus, filed with the U.S. Securities and Exchange Commis ...

The gross proceeds of the offering are approximately $1.1 million before deducting placement agent fees and other estimated offering expenses payable by the Company. The Company intends to use the net proceeds from the offering to fund the continued development of its ONP-002 product candidate and for general corporate purposes and working capital. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or j ...

SARASOTA, Fla., June 25, 2024 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological disorders, today announced that it has entered into a placement agency agreement for the purchase and sale of 1,100,000 shares of its common stock (or pre-funded warrants in lieu thereof) at an offering price of $1.00 per share. The closing of the public offering is expected to occur on or about June 26, 2024, subject to ...

The gross proceeds of the offering are anticipated to be approximately $1,100,000 million before deducting placement agent fees and other estimated offering expenses payable by the Company. The Company intends to use the net proceeds from the offering to fund the continued development of its ONP-002 product candidate and for general corporate purposes and working capital. The offering is being made pursuant to a shelf registration statement on Form S-3 (File No. 333-269225), including a base prospectus, fil ...

SARASOTA, Fla., June 24, 2024 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE: OGEN) ("Oragenics" or the "Company"), a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological disorders, today announced that it intends to offer and sell shares of its common stock (or prefunded warrants in lieu thereof). All of the securities to be sold in the offering are to be offered by Oragenics. The offering is subject to market conditions, and there can be no assurance as to whether ...

The Company intends to use the net proceeds from the offering to fund the continued development of its ONP002 product candidate and for general corporate purposes and working capital. The offering is being made pursuant to a shelf registration statement on Form S-3 (File No. 333-269225), including a base prospectus, filed with the U.S. Securities and Exchange Commission (the "SEC") on January 13, 2023, and declared effective on January 25, 2023. The offering will be made only by means of a prospectus supple ...

Company Overview - Oragenics is a development-stage biotechnology company focused on nasal delivery of pharmaceutical medications targeting neurological disorders and infectious diseases, including drug candidates for mild traumatic brain injury (mTBI) and Niemann Pick Disease Type C (NPC) [1] Compliance with NYSE American - The NYSE American has reviewed Oragenics' compliance plan submitted on May 17, 2024, and determined that the company has made a reasonable demonstration of its ability to regain compliance by October 18, 2025 [2] - During the compliance period, Oragenics will be subject to quarterly monitoring, and failure to regain compliance by the deadline may result in delisting proceedings [2][4] Recent Developments - On June 18, 2024, Oragenics received a notice from the NYSE American confirming acceptance of its plan to regain compliance with the continued listing standards [4]

SARASOTA, Fla., May 22, 2024 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE:OGEN), a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological disorders, today announced it has appointed Dr. William "Frank" Peacock as its Chief Clinical Officer, who will conduct its anticipated Phase II clinical trial for treating concussion in the Emergency Department ("ED"). Oragenics' lead drug candidate, ONP-002, is combined with its intranasal device intended for the treatment of mil ...

Core Insights - Oragenics, Inc. has appointed Dr. William "Frank" Peacock as Chief Clinical Officer to lead its Phase II clinical trial for ONP-002, aimed at treating concussions in emergency departments [1][4] - ONP-002 is a new chemical entity designed for intranasal delivery to treat mild Traumatic Brain Injury (mTBI), with a completed Phase I study indicating it is safe and well-tolerated [1][5] - The global incidence of concussions is significant, with an estimated 69 million cases reported annually, highlighting an unmet medical need in this area [6] Company Overview - Oragenics is a development-stage biotechnology company focused on nasal delivery of pharmaceuticals for neurological disorders and infectious diseases, including treatments for mTBI and Niemann Pick Disease Type C [7] - The company is collaborating with Avance Clinical, a Contract Research Organization (CRO), for its Phase II trial [4] Clinical Development - The Phase II trial for ONP-002 will assess the timing of the first dose, the relationship between drug application and blood biomarker levels, and the evaluation of patient symptom severity shortly after injury [5] - Dr. Peacock's expertise in emergency medicine and blood biomarkers is expected to enhance the success of the clinical trials [4][3]

Oragenics is a development-stage biotechnology company focused on nasal delivery of pharmaceutical medications in neurology and fighting infectious diseases, including drug candidates for treating mild traumatic brain injury (mTBI), also known as concussion, and for treating Niemann Pick Disease Type C (NPC), as well as proprietary powder formulation and an intranasal delivery device. For more information, please visit www.oragenics.com. Webinar Topic: Neurotrauma Medicine When: Monday, May 20, 2024 Time: 1 ...